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Implications for prevention
T
he excess risk for future coronary
heart disease (CHD) events attribut-
able to diabetes alone in the absence
of coexisting CHD was not well under-
stood until the publication by Haffner
et al. (1) on this subject in 1998, which
concluded that the elevation in risk was
essentially similar to nondiabetic individ-
uals with a prior myocardial infarction.
This conclusion was based on a nonsig-
niﬁcant adjusted hazard ratio of 1.2 for
CHD mortality over 7 years of follow-up in
a Finnish cohort. This article had a con-
siderable impact on our thinking and ap-
proach to CHD prevention in diabetes
givenitspublicationinaprestigiousmed-
ical journal and high number of citations
since (n 5 3,676; scholar.google.com,ac-
cessed 4 October 2010). It provided jus-
tiﬁcation for taking the same intensive
approach to CHD prevention as used in
individuals with a prior myocardial
infarction, including aspirin as a corner-
stone of treatment. In apparently equiva-
lent high-risk states of diabetes and prior
CHD, the beneﬁt of aspirin in reducing
risk of myocardial infarction has been be-
lieved to outweigh uncommon bleeding
complications and yield a net average ex-
pected beneﬁt. Given the ﬁnding of
Haffner et al. and previous American Di-
abetes Association (ADA) recommenda-
tions in favor of the use of aspirin to
prevent CHD in many individuals with
diabetes, why then would a recent ADA
position statement change course by rec-
ommending more limited aspirin use
based on overall cardiovascular disease
( C V D )r i s k( 2 , 3 ) ?
A number of reasons seem to justify
this change in recommendations. There
have been major advances in treatment
approaches to type 2 diabetes, replica-
tions of the ﬁnding by Haffner et al. are
inconsistent, and recent data suggest that
the utility of aspirin for CHD prevention
may be of a lesser magnitude than pre-
viously believed. First, it should be
pointed out that even though the article
by Haffner et al. was published in 1998,
the data used for this analysis were
generated in Finland between 1982 and
1990 (1). This was the pre-Diabetes Con-
trol and Complications Trial (DCCT) and
pre-UK Prospective Diabetes Study
(UKPDS) era, and the mean fasting glu-
cose value of 210 mg/dL in individuals
with diabetes and no CHD history in the
Finnish cohort reﬂects this fact, and this
valuewouldbeinconsistentwiththelevel
of glucose control currently recom-
mended (4–6). Also, all diabetic subjects
were medication treated, thereby rep-
resenting a group with greater disease bur-
den than would be seen in all individuals
with diabetes, including those maintained
on lifestyle therapy. Third, presence of
prior CHD was sought only in individuals
who reported a previous hospital admis-
sion for evaluation of chest pain. Given
that diabetes is known to be associated
with a higher frequency of silent myo-
cardial infarction, this strategy may
have resulted in misclassiﬁcation of past
myocardial infarction. The Fenoﬁbrate
Intervention and Event Lowering in Di-
abetes (FIELD) study demonstrated that
over a third of new cases of myocardial
infarction that occurred during this trial
in individuals with diabetes were silent
(7).Itislikely,therefore,thatthediabetic
group without CHD did in fact contain
a substantial unknown number of indi-
viduals with silent CHD. This proportion
was likely further increased by poorer
glycemic control—a known modiﬁable
predictor of CHD risk as learned from
both the DCCT and UKPDS clinical trials
(8,9). If these individuals had been ex-
cluded and correctly classiﬁed, the risk
forfutureCHDamongthediabeticgroup
would have certainly been lower.
Perhaps not surprisingly, attempts to
replicate the ﬁnding of Haffner et al. have
for the most part been unsuccessful. A
recentmeta-analysisofstudiescomparing
CHD risk in individuals with diabetes with
those with prior myocardial infarction but
without diabetes reported signiﬁcantly
lower overall relative odds of CHD events
in the individuals with diabetes (10). A
total of 13 studies comprising 45,108
patients met the inclusion and exclusion
criteria for this meta-analysis, with a cal-
culated overall odds ratio for fatal or non-
fatal myocardial infarction of 0.56 (95%
CI 0.53–0.60) comparing individuals
with diabetes alone with those with prior
myocardial infarction and without diabe-
tes(10).Ofthe13studiesincluded,11re-
portedsigniﬁcantlyloweroddsofincident
CHD among individuals with diabetes
(10). In addition, another recent prospec-
tive study conducted in Spain found a
hazard ratio of 0.33 for fatal or nonfatal
myocardial infarction in individuals with
type 2 diabetes compared with nondia-
betic individuals with a prior myocardial
infarction (11). In most populations, it
now seems safe to conclude that diabetes
is not the equivalent of prior myocardial
infarction with respect to future risk of
CHD.
Diabetes need not be a CHD equiva-
lent to merit prophylactic aspirin treat-
ment to prevent myocardial infarction if
the potential beneﬁts of this preventive
treatment outweigh the risks. The ADA
committee that recently evaluated this
subject performed a meta-analysis that
incorporated the most recent aspirin
clinical trial data among patients with
diabetes to assist with their decision. The
overall risk ratio of CHD events for the
nine studies included was 0.91 (95% CI
0.79–1.05),consistentwithnosigniﬁcant
reduction in risk of these outcomes with
aspirin use (3). A similar nonsigniﬁcant
result was seen with regard to prevention
of stroke with aspirin. Furthermore, aspi-
rin use was not as safe as previously pre-
sumed. Rates of extracranial bleeding
complications appeared to be ;50%
higher among individuals with diabetes
compared with those without in the An-
tithrombotic Trialists’ Collaboration
meta-analysis (12).
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Editorials
EDITORIALGiven concerns about the miniscule
magnitude of beneﬁt and the moderate
potential for bleeding complications in
individuals with diabetes, the 2010 ADA
position statement recommended more
l i m i t e du s eo fa s p i r i nt h a np r e v i o u s l y
advised in 2007 (2). The current state-
ment recommends aspirin for individuals
with diabetes whose CVD risk exceeds
10% and who are not at higher risk for
gastrointestinal bleeding (3). Diabetic in-
dividuals at this level of elevated CVD risk
would generally include men over age
50 years and women over age 60 years
with one or more additional major CVD
risk factors (hypertension, smoking, dys-
lipidemia, albuminuria, and family history
of CVD), although treatment of these risk
factorsmaylowertheCVDriskleveltoless
than 10%. Aspirin was not recommended
fordiabeticmenaged50yearsandyounger
and women aged 60 years and younger
without additional CVD risk factors. For-
merly, the ADA recommendation included
aspirin treatment for individuals with
diabetes over age 40 years or with any
additional CVD risk factor, but not for in-
dividuals younger than age 21 years be-
cause of concerns about risk of Reyes
syndrome (2).
Onecouldargueastowhyaspirinuse
was recommended at all for individuals
with diabetes given the lack of clearly
demonstrated beneﬁt. We think that the
counterargument is that deﬁnitive re-
search to rule out a beneﬁt has not been
performed, and that currently available
data suggest a small but as yet unproven
effect that can be balanced against poten-
tial harms for individual patients.
The 2010 ADA position statement
on aspirin use recommends risk estima-
tion in making the decision to prescribe
treatment and refers readers to several
currently available models including the
UKPDS Risk Engine, the Atherosclerosis
Risk in Communities (ARIC) CHD Risk
Calculator, and the ADA Diabetes Per-
sonal Health Decisions (PHD) (3). It is
likely that we will increasingly be using
such estimation for more personalized
clinical medicine in the future. The pro-
liferation of prediction models permits
assessment of risk with much less gran-
ularity than has been available previ-
ously. Furthermore, the progress of
genomics and personalized medicine
has the potential to lead to signiﬁcant
advances in pharmacogenetic proﬁling
to predict the effectiveness or risks of
speciﬁcmedication treatmentorforpre-
vention (13). Such developments hold
promise for the application of treat-
mentswithbeneﬁtsthatmorelikelyout-
weigh risks.
The equating of diabetes to prior
myocardial infarction in terms of future
CHDriskbyHaffneretal.seemstobeone
reason that their article generated enor-
mous interest in the subject. The New
England Journal of Medicine (NEJM)
article by Haffner et al. has received
more citations than the 3,267 received
by the 2002 NEJM article from the Dia-
betes Prevention Program reporting
the beneﬁts of a lifestyle intervention or
metformininpreventingdiabetesinindi-
viduals at higher risk (scholar.google.
com, accessed 8 October 2010) (14).
Would the article have received the
same degree of interest if the results
were presented numerically instead as
20.2 incident cases per 100 person-years
for diabetes present, prior CHD absent
compared with 18.8 per 100 person-
years for diabetes absent, prior CHD
present? We think not. Framing refers
to the presentation of identical risk infor-
mation in different ways and has been
shown to affect judgment and choices
(15). The analogy drawn between diabe-
tes and heart disease makes it immedi-
ately apparent that CHD risk is seriously
elevated in diabetes, an observation very
familiar to health care providers. Inter-
pretation of risk information conveyed
as relative risks, absolute risks, or other
quantitative measures has been shown to
be inconsistent, and at times incorrect,
even by individuals with excellent nu-
meracy skills (16). One can also reframe
the risks of aspirin use by comparing it
with a more familiar experience. This has
been done only once to our knowledge,
and it was concluded that using aspirin is
about as dangerous as driving in a car
as judged by similarity of fatality rates
(17). Alternatively one can examine the
point at which aspirin-related adverse
events would occur more frequently
than CVD occurrences prevented. This
would be expected when the annual
C V Dr i s ki s1 %o rl e s s( 3 ) .W h e t h e rr e -
framing of the risk of aspirin use in these
terms would lead to greater or lesser
enthusiasm for its use has not been
examined.
The quest for the best approaches to
prevent vascular complications in indi-
viduals with diabetes is a continuing
pursuit. The recent change in ADA rec-
ommendations seems well justiﬁed by
continuingprogressinourunderstanding
of the magnitude of excess CHD risk in
individuals with diabetes and the beneﬁts
and risks of aspirin treatment.
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